Friday, 9 December 2022 14.00 - 16.00 h
This guideline describes the information to be documented when an application for a marketing authorisation for recombinant or human plasma-derived factor VIII products is made for use in treatment and prevention of bleeding in patients with haemophilia A. The guidance covers clinical investigations to be conducted pre- and post-marketing authorisation. Guidance is also provided for authorised products where a significant change in the manufacturing process has been made.
For further details please see the "Guideline on the clinical investigation of recombinant and human plasma-derived factor VIII products".